Table 5.
Statistical Analysis of the Improvement in Rank
| Therapeutic Use | N | Mean Improvement | StdDev | tValue | P |
|---|---|---|---|---|---|
| analgesic | 29 | 90.43 | 117.55 | 4.14 | 0.0003 |
| anti-inflammatory | 160 | 30.12 | 115.04 | 3.31 | 0.0011 |
| anti-psychotic (neurole) | 69 | 25.57 | 73.36 | 2.90 | 0.0051 |
| immunosuppressive agent | 67 | 7.96 | 40.42 | 1.61 | 0.1120 |
| tranquilizer | 68 | 14.43 | 73.95 | 1.61 | 0.1124 |
| cardiovascular agent | 22 | 10.82 | 69.37 | 0.73 | 0.4726 |
| anti-neoplastic | 54 | 10.33 | 114.65 | 0.66 | 0.5106 |
| anti-convulsant | 144 | -4.50 | 92.09 | -0.59 | 0.5585 |
| anti-proliferative | 86 | -1.86 | 77.86 | -0.22 | 0.8252 |
A paired t-test was performed to analyze the difference in the rank of true positives returned by the direct and indirect method. N is the number of true positives found within the top 100 results across the whole therapeutic group. Improvement is the average improvement (rank direct - rank indirect).